

Louisiana MCO Physician Administered Drug List

Updated: November 1, 2024

Implementation: September 1, 2024			
Brand Name	Generic Name	Route	Drug Class
ADUHELM	aducanumab-avwa	IV	Alzheimer's Disease Therapy - Amyloid Directed Monoclonal Antibody
EYLEA	aflibercept	IO	Ophthalmic - Macular Degeneration, Age-Related, Therapy Agents
EYLEA HD	aflibercept	IO	Ophthalmic - Macular Degeneration, Age-Related, Therapy Agents
CAMPATH	alemtuzumab	IV	Antineoplastic - CD52 Specific Recombinant Monoclonal Antibody Agents
LEMTRADA	alemtuzumab	IV	Multiple Sclerosis Agent - CD52 Specific Monoclonal Antibody
ZEMAIRA	alpha-1-proteinase inhibitor	IV	Elastase Inhibitors
ARALAST NP	alpha-1-proteinase inhibitor	IV	Elastase Inhibitors
PROLASTIN C	alpha-1-proteinase inhibitor	IV	Elastase Inhibitors
ERAXIS	anidulafungin	IV	Antifungal - Glucan Synthesis Inhibitor, Echinocandins
LENMELDY	atidarsagene autotemcel	IV	Gene Therapy Agents - CD34+ Hematopoietic Stem Cells (HSCs)
ZYNTEGLO	betibeglogene autotemcel	IV	Gene Therapy Agents - CD34+ Hematopoietic Stem Cells (HSCs)
ADCETRIS	brentuximab vedotin	IV	Antineoplastic - Antibody-Drug Conjugates (ADCs)
CRYSVITA	burosumab-twza	SQ	Fibroblast Growth Factor 23 (FGF23) Inhibitors, Monoclonal Antibody
ILARIS	canakinumab/PF	SQ	Anti-inflammatory - Interleukin-1 Beta Blockers
CABLIVI	caplacizumab-yhdp	IJ	Agents to Treat aTTP- anti von Willebrand Factor (vWF) A1 domain
AMONDYS-45	casimersen	IV	Duchenne Muscular Dystrophy - Exon Skipping Antisense Oligonucleotide
CANCIDAS	caspofungin acetate	IV	Antifungal - Glucan Synthesis Inhibitor, Echinocandins
CASPOFUNGIN ACETATE	caspofungin acetate	IV	Antifungal - Glucan Synthesis Inhibitor, Echinocandins
CISPLATIN	cisplatin	IV	Antineoplastic - Platinum Complexes

Implementation: September 1, 2024

Brand Name	Generic Name	Route	Drug Class
KEMOPLAT	cisplatin	IV	Antineoplastic - Platinum Complexes
DALVANCE	dalbavancin HCl	IV	Lipoglycopeptide Antibiotics
DAPTOMYCIN	daptomycin	IV	Cyclic Lipopeptide Antibiotics
CUBICIN	daptomycin	IV	Cyclic Lipopeptide Antibiotics
CUBICIN RF	daptomycin	IV	Cyclic Lipopeptide Antibiotics
DAPTOMYCIN-0.9% NACL	daptomycin in 0.9 % sodium chloride	IV	Cyclic Lipopeptide Antibiotics
DARZALEX	daratumumab	IV	Antineoplastic - CD38 Specific Recombinant Monoclonal Antibody Agents
DAUNORUBICIN HCL	daunorubicin HCl	IV	Antineoplastic Antibiotic - Anthracyclines
ELEVIDYS	delandistrogene moxeparvovec-rokl	IV	Duchenne Muscular Dystrophy - Gene Therapy Agents
XGEVA	denosumab	SQ	RANK ligand (RANKL) inhibitor, MC Antibody
JEMPERLI	dostarlimab-gxly	IV	Antineoplastic-Anti-Programmed Cell Death Receptor-1 (PD-1) MC Antib.
DOXORUBICIN HCL	doxorubicin HCl	IV	Antineoplastic Antibiotic - Anthracyclines
ADRIAMYCIN	doxorubicin HCl	IV	Antineoplastic Antibiotic - Anthracyclines
DOXIL	doxorubicin HCl pegylated liposomal	IV	Antineoplastic Antibiotic - Anthracyclines
DOXORUBICIN HCL LIPOSOME	doxorubicin HCl pegylated liposomal	IV	Antineoplastic Antibiotic - Anthracyclines
CAELYX	doxorubicin HCl pegylated liposomal	IV	Antineoplastic Antibiotic - Anthracyclines
IMFINZI	durvalumab	IV	Antineoplastic-Anti-Programmed Cell Death Ligand-1 (PD-L1) MC Antib.
SOLIRIS	eculizumab	IV	Agents to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)
VYVGART	efgartigimod alfa-fcab	IV	Antimyasthenic Agent - Neonatal Fc Receptor (FcRn) Inhibitor

Implementation: September 1, 2024

Brand Name	Generic Name	Route	Drug Class
VYVGART HYTRULO	efgartigimod alfa-hyaluronidase-qvfc	SQ	Antimyasthenic Agent - Neonatal Fc Receptor (FcRn) Inhibitor
SKYSONA	elivaldogene autotemcel	IV	Gene Therapy Agents - CD34+ Hematopoietic Stem Cells (HSCs)
PADCEV	enfortumab vedotin-ejfv	IV	Antineoplastic - Antibody-Drug Conjugates (ADCs)
HEMGENIX	etranacogene dezaparvovec-drlb	IV	Gene Therapy Agents - Factor IX Deficiency
CASGEVY	exagamglogene autotemcel	IV	Sickle Cell Anemia Agents - Cell/Gene Therapy
ENHERTU	fam-trastuzumab deruxtecan-nxki	IV	Antineoplastic - Antibody-Drug Conjugates (ADCs)
KCENTRA	human prothrombin complex concentrate (PCC), 4-factor	IV	Factor IX Complex (Prothrombin Complex Concentrate) Preparations
ABECMA	idecabtagene vicleucel	IV	Antineoplastic - BCMA directed CAR-T cell immunotherapy
UPLIZNA	inebilizumab-cdon	IV	Immunosuppressive - CD19 (B Lymphocyte) Monoclonal Antibody
ALDURAZYME	laronidase	IV	Metabolic Disease Enzyme Replacement, Mucopolysaccharidosis
LYFGENIA	lovotibeglogene autotemcel	IV	Sickle Cell Anemia Agents - Cell/Gene Therapy
ZEPZELCA	lurbinectedin	IV	Antineoplastic-Alkylating Agent-Tetrahydroisoquinoline and Derivatives
MICAFUNGIN	micafungin sodium	IV	Antifungal - Glucan Synthesis Inhibitor, Echinocandins
MYCAMINE	micafungin sodium	IV	Antifungal - Glucan Synthesis Inhibitor, Echinocandins
DANYELZA	naxitamab-gqqk	IV	Antineoplastic - Anti-GD2 Ganglioside Monoclonal Antibody
OCREVUS	ocrelizumab	IV	Multiple Sclerosis Agent - CD20 Specific Monoclonal Antibody
ARZERRA	ofatumumab	IV	Antineoplastic - CD20 Specific Recombinant Monoclonal Antibody Agents
ZOLGENSMA	onasemnogene abeparvovec-xioi	IV	Gene Therapy Agents - SMN Protein Deficiency

Implementation: September 1, 2024

Brand Name	Generic Name	Route	Drug Class
PACLITAXEL PROTEIN-BOUND	paclitaxel protein-bound	IV	Antineoplastic - Taxanes
ABRAXANE	paclitaxel protein-bound	IV	Antineoplastic - Taxanes
KRYSTEXXA	pegloticase	IV	Hyperuricemia Therapy - Urate-Oxidase Enzyme-Type
KEYTRUDA	pembrolizumab	IV	Antineoplastic-Anti-Programmed Cell Death Receptor-1 (PD-1) MC Antib.
ALIMTA	pemetrexed disodium	IV	Antineoplastic - Antimetabolite - Folic Acid Analogs
AXTLE	pemetrexed dipotassium	IV	Antineoplastic - Antimetabolite - Folic Acid Analogs
PEMETREXED DISODIUM	pemetrexed disodium	IV	Antineoplastic - Antimetabolite - Folic Acid Analogs
PEMRYDI RTU	pemetrexed disodium	IV	Antineoplastic - Antimetabolite - Folic Acid Analogs
ULTOMIRIS	ravulizumab-cwvz	IV	Agents to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)
RITUXAN	rituximab	IV	Antineoplastic - CD20 Specific Recombinant Monoclonal Antibody Agents
RITUXAN HYCELA	rituximab/hyaluronidase, human recombinant	SQ	Antineoplastic - CD20 Specific Recombinant Monoclonal Antibody Agents
TALVEY	talquetamab-tgvs	SQ	Bispecific GPRC5D-Directed CD3 T-cell Engager, Monoclonal Antibody
TEPEZZA	teprotumumab-trbw	IV	Thyroid Eye Disease Agents
RETHYMIC	thymus tissue-agdc	IL	Thymus Tissue Replacement
KYMRIAH	tisagenlecleucel	IV	Antineoplastic - CD-19 directed CAR-T cell immunotherapy
HERCEPTIN	trastuzumab	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody
ROCTAVIAN	valoctocogene roxaparvovec-rvox	IV	Gene Therapy Agents - Factor VIII Deficiency
VILTEPSO	viltolarsen	IV	Duchenne Muscular Dystrophy - Exon Skipping Antisense Oligonucleotide

Implementation: November 1, 2024

Brand Name	Generic Name	Route	Drug Class
ADENOSINE	adenosine	IV	Antiarrhythmic Others
KADCYLA	ado-trastuzumab emtansine	IV	Antineoplastic - Antibody-Drug Conjugates (ADCs)
TECELRA	afamitresgene autoleucel	IV	Antineoplastic - MAGE-A4 directed TCR-T cell immunotherapy
FABRAZYME	agalsidase beta	IV	Metabolic Disease Enzyme Replacement, Fabry's Disease
LUMIZYME	alglucosidase alfa	IV	Metabolic Disease Enzyme Replacement, Pompe Disease
ETHYOL	amifostine crystalline	IV	Urinary Tract Protective Agents used in conjunction with Chemotherapy
AMIKACIN SULFATE	amikacin sulfate	IJ	Aminoglycoside Antibiotic
AMPICILLIN SODIUM	ampicillin sodium	IJ	Aminopenicillin Antibiotic
THYMOGLOBULIN	anti-thymocyte globulin, rabbit	IV	Immune Serums
CROFAB	antivenin, crotalidae Fab(ovine)	IJ	Antivenoms - Snake Antivenoms
TRISENOX	arsenic trioxide	IV	Antineoplastic - Arsenic Compounds
ERWINAZE	asparaginase (Erwinia chrysanthemi)	IJ	Antineoplastic - Asparaginase Enzyme Therapy Agents
RYLAZE	asparaginase Erwinia chrysanthemi (recombinant)-rywn	IM	Antineoplastic - Asparaginase Enzyme Therapy Agents
TECENTRIQ	atezolizumab	IV	Antineoplastic-Anti-Programmed Cell Death Ligand-1 (PD-L1) MC Antib.
ATROPEN	atropine sulfate	IM	Muscarinic Receptor Antagonists (Anticholinergic)
NEXVIAZYME	avalglucosidase alfa-ngpt	IV	Metabolic Disease Enzyme Replacement, Pompe Disease
BAVENCIO	avelumab	IV	Antineoplastic-Anti-Programmed Cell Death Ligand-1 (PD-L1) MC Antib.
YESCARTA	axicabtagene ciloleucel	IV	Antineoplastic - CD-19 directed CAR-T cell immunotherapy
VIDAZA	azacitidine	IJ	Antineoplastic - Antimetabolite - Pyrimidine Analogs

Implementation: November 1, 2024

Brand Name	Generic Name	Route	Drug Class
GABLOFEN	baclofen	IT	Skeletal Muscle Relaxant - Central Muscle Relaxants
BCG VACCINE (TICE STRAIN)	BCG vaccine, live/PF	IJ	Vaccine Bacterial - Other
BLENREP	belantamab mafodotin-blmf	IV	Antineoplastic - Antibody-Drug Conjugates (ADCs)
BELEODAQ	belinostat	IV	Antineoplastic - Histone deacetylase (HDAC) inhibitors
TREANDA/BENDEKA	bendamustine HCl	IV	Antineoplastic - Alkylating Agent - Other
VYJUVEK	beremagene geperpavec-svdt	TP	Dermatological - Gene Therapy Agents
AVASTIN	bevacizumab	IV	ANP - Human Vascular Endothelial Growth Factor Inhib Rec-MC Antibody
VEGZELMA	bevacizumab-adcd	IV	ANP - Human Vascular Endothelial Growth Factor Inhib Rec-MC Antibody
MVASI	bevacizumab-awwb	IV	ANP - Human Vascular Endothelial Growth Factor Inhib Rec-MC Antibody
ZIRABEV	bevacizumab-bvzr	IV	ANP - Human Vascular Endothelial Growth Factor Inhib Rec-MC Antibody
ALYMSYS	bevacizumab-maly	IV	ANP - Human Vascular Endothelial Growth Factor Inhib Rec-MC Antibody
BLEOMYCIN SULFATE	bleomycin sulfate	IJ	Antineoplastic Antibiotic - Others
BLINCYTO	blinatumomab	IV	Bispecific CD19-Directed CD3 T-cell Engager, Monoclonal Antibody
VELCADE	bortezomib	IJ	Antineoplastic - Proteasome Enzyme Inhibitors
TECARTUS	brexucabtagene autoleucel	IV	Antineoplastic - CD-19 directed CAR-T cell immunotherapy
BEOVU	brolocizumab-dbll	IO	Ophthalmic - Macular Degeneration, Age-Related, Therapy Agents
BUSULFEX	busulfan	IV	Antineoplastic - Alkylating Agent - Alkyl Sulfonates
JEVTANA	cabazitaxel	IV	Antineoplastic - Taxanes
ASPARLAS	calaspargase pegol-mknl	IV	Antineoplastic - Asparaginase Enzyme Therapy Agents
CALCITRIOL	calcitriol	IV	Vitamins - D Derivatives

Implementation: November 1, 2024

Brand Name	Generic Name	Route	Drug Class
CALCIUM GLUCONATE	calcium gluconate	IV	Minerals and Electrolytes - Calcium Replacement
PARAPLATIN	carboplatin	IV	Antineoplastic - Platinum Complexes
KYPROLIS	carfilzomib	IV	Antineoplastic - Proteasome Enzyme Inhibitors
BICNU	carmustine	IV	Antineoplastic-Alkylating Agent
ANCEF	cefazolin sodium	IV	Cephalosporin Antibiotics – 1st Generation
FETROJA	cefiderocol sulfate tosylate	IV	Cephalosporin Antibiotics - Siderophore
CLAFORAN	cefotaxime sodium	IJ	Cephalosporin Antibiotics – 3rd Generation
CEFOTAN	cefotetan disodium	IJ	Cephalosporin Antibiotics – 2nd Generation
TEFLARO	ceftaroline fosamil acetate	IV	Cephalosporin Antibiotics - 5th Generation
MEFOXIN	Ceftoxitin	IJ	Cephalosporin Antibiotics – 2nd Generation
LIBTAYO	cemiplimab-rwlc	IV	Antineoplastic-Anti-Programmed Cell Death Receptor-1 (PD-1) MC Antib.
BRINEURA	cerliponase alfa	IJ	Drugs to Treat Neuronal Ceroid Lipofuscinosis type 2 (CLN2)
ERBITUX	cetuximab	IV	Epidermal Growth Factor Recept Blocker (HER-1 Type), Rec-MC Antibody
CHLORMYCETIN SODIUM SUCCINATE	chloramphenicol sod succinate	IV	Chloramphenicol Antibiotics and Derivatives - Single Agents
CARVYKTI	ciltacabtagene autoleucel	IV	Antineoplastic - BCMA directed CAR-T cell immunotherapy
CIPROFLOXACIN-D5W	ciprofloxacin lactate/dextrose 5 % in water	IV	Fluoroquinolone Antibiotics
MAVENCLAD	cladribine	IV	Antineoplastic - Antimetabolite - Purine Analogs
CLOLAR	clofarabine	IV	Antineoplastic - Antimetabolite - Purine Analogs
ALIQOPA	copanlisib	IV	Antineoplastic - Phosphatidylinositol 3-Kinase (PI3K) Inhibitors
CYTOXAN	cyclophosphamide	IV	Antineoplastic - Alkylating Agent - Nitrogen Mustards

Implementation: November 1, 2024

Brand Name	Generic Name	Route	Drug Class
CYCLOSPORINE	cyclosporine	IV	Immunosuppressive - Calcineurin Inhibitors
CYTARABINE	cytarabine/PF	IJ	Antineoplastic - Antimetabolite - Pyrimidine Analogs
DACARBAZINE	dacarbazine	IV	Antineoplastic - Alkylating Agent - Triazenes
COSMEGEN	dactinomycin	IV	Antineoplastic Antibiotic - Actinomycins
VYXEOS	daunorubicin/cytarabine liposomal	IV	Antineoplastic - Antibiotic and Antimetabolite Combinations
DECITABINE	decitabine	IV	Antineoplastic - Antimetabolite - Pyrimidine Analogs
DACOGEN	decitabine	IV	Antineoplastic - Antimetabolite - Pyrimidine Analogs
FIRMAGON	degarelix acetate	SQ	Antineoplastic - LHRH (GnRH) Antagonist Pituitary Suppressants
TOTECT/ZINECARD	dexrazoxane HCl	IV	Tissue Protective Agents for Tx of Cancer Chemotherapy Extravasation
DEXTROSE IN LACTATED RINGERS	dextrose 5 % in lactated ringers	IV	Dextrose and Lactated Ringer's Solutions
DEXTROSE IN RINGERS INJECTION	dextrose 5 % in Ringer's	IV	Minerals and Electrolytes - Electrolytes and Dextrose
TAXOTERE	docetaxel	IV	Antineoplastic - Taxanes
EMPLICITI	elotuzumab	IV	Antineoplastic - Anti-SLAMF7 Monoclonal Antibody Agents
GAMIFANT	emapalumab-lzsg	IV	Immunosuppressive - Interferon Inhibitor, Monoclonal Antibody
EPINEPHRINE	epinephrine	IV	Cardiovascular Sympathomimetics
ELLENCÉ	epirubicin HCl	IV	Antineoplastic Antibiotic - Anthracyclines
XERAVA	eravacycline di-hydrochloride	IV	Tetracycline Antibiotics
HALAVEN	eribulin mesylate	IV	Antineoplastic - Microtubule Inhibitors
ERYTHROCIN LACTOBIONATE	erythromycin lactobionate	IV	Macrolide Antibiotics

Implementation: November 1, 2024

Brand Name	Generic Name	Route	Drug Class
EXONDYS-51	eteplirsen	IV	Duchenne Muscular Dystrophy - Exon Skipping Antisense Oligonucleotide
TOPOSAR	etoposide	IV	Antineoplastic - Epipodophyllotoxins
VABYSMO	faricimab-svoa	IO	Bispecific VEGF-A and Angiopoietin-2 (Ang-2) Inhibitors
TRIFERIC	ferric pyrophosphate citrate	HE	Minerals and Electrolytes - Iron
BEQVEZ	fidanacogene elaparvovec-dzkt	IV	Gene Therapy Agents - Factor IX Deficiency
FLOXURIDINE	floxuridine	IJ	Antineoplastic - Antimetabolite - Pyrimidine Analogs
DIFLUCAN	fluconazole	IV	Antifungal - Triazoles
FLUDARABINE PHOSPHATE	fludarabine phosphate	IV	Antineoplastic - Antimetabolite - Purine Analogs
ADRUCIL	fluorouracil	IV	Antineoplastic - Antimetabolite - Pyrimidine Analogs
ADRUCIL	fluorouracil	IV	Antineoplastic - Antimetabolite - Pyrimidine Analogs
FASLODEX	fulvestrant	IM	Antineoplastic - Selective Estrogen Receptor Degraders (SERDs)
NAGLAZYME	galsulfase	IV	Metabolic Disease Enzyme Replacement, Mucopolysaccharidosis
INFUGEM	gemcitabine HCl in 0.9 % sodium chloride	IV	Antineoplastic - Antimetabolite - Pyrimidine Analogs
GENTAMICIN SULFATE	gentamicin sulfate	IJ	Aminoglycoside Antibiotic
VYONDYS-53	golodirsen	IV	Duchenne Muscular Dystrophy - Exon Skipping Antisense Oligonucleotide
ZOLADEX	goserelin acetate	SQ	Antineoplastic - LHRH (GnRH) Agonist Analog Pituitary Suppressants
HEPARIN FLUSH	heparin sodium, porcine in 0.9 % sodium chloride	IV	Heparin Flush Formulations

Implementation: November 1, 2024

Brand Name	Generic Name	Route	Drug Class
HEPARIN SODIUM-D5W	heparin sodium, porcine/dextrose 5 % in water	IV	Heparins
HEPARIN SODIUM	heparin sodium,porcine	IJ	Heparins
VANTAS	histrelin acetate	IL	Antineoplastic - LHRH (GnRH) Agonist Analog Pituitary Suppressants
TROGARZO	ibalizumab-uiyk	IV	Antiretroviral - Anti-CD4 Domain 2 Monoclonal Antibody
IDAMYCIN PFS	idarubicin HCl	IV	Antineoplastic Antibiotic - Anthracyclines
ELAPRASE	idursulfase	IV	Metabolic Disease Enzyme Replacement, Mucopolysaccharidosis
IFEX	ifosfamide	IV	Antineoplastic - Alkylating Agent - Nitrogen Mustards
PRIMAXIN	imipenem/cilastatin sodium	IV	Carbapenem Antibiotic Combinations
BESPONSA	inotuzumab ozogamicin	IV	Antineoplastic - Antibody-Drug Conjugates (ADCs)
INTRON A	interferon alfa-2b, recomb.	IJ	Antineoplastic - Interferons
YERVOY	ipilimumab	IV	Antineoplastic - Cytotoxic T-Lymphocyte antigen (CTLA-4),R-MC Antibody
CAMPTOSAR	irinotecan HCl	IV	Antineoplastic - Topoisomerase I Inhibitors
ONIVYDE	irinotecan liposomal	IV	Antineoplastic - Topoisomerase I Inhibitors
VENOFER	iron sucrose complex	IV	Minerals and Electrolytes - Iron
SARCLISA	isatuximab-irfc	IV	Antineoplastic - CD38 Specific Recombinant Monoclonal Antibody Agents
CRESEMBA	isavuconazonium sulfate	IV	Antifungal - Triazoles
IXEMPRA	ixabepilone	IV	Antineoplastic - Epothilones and Analogs
XENLETA	lefamulin acetate	IV	Pleuromutilin Antibiotics
LEVAQUIN	levofloxacin	IV	Fluoroquinolone Antibiotics
KHAPZORY	levoleucovorin	IV	Methotrexate Rescue Agents
FUSILEV	levoleucovorin calcium	IV	Methotrexate Rescue Agents

Implementation: November 1, 2024

Brand Name	Generic Name	Route	Drug Class
AMTAGVI	lifileucel	IV	Antineoplastic - CD4 and CD8 Tumor-Derived T-cell immunotherapy
LINCOCIN	lincomycin HCl	IJ	Lincosamide Antibiotics
ZYVOX	linezolid in dextrose 5 % in water	IV	Oxazolidinone Antibiotics
BREYANZI	lisocabtagene maraleucel	IV	Antineoplastic - CD-19 directed CAR-T cell immunotherapy
ATGAM	lymphocyte immune globulin, antithymocyte (equine)	IV	Immune Serums
OSMITROL	mannitol	IV	Diuretic - Osmotic
MARGENZA	margetuximab-cmkb	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody
PEPAXTO	melphalan flufenamide	IV	Antineoplastic-Alkylating Agent
ALKERAN	melphalan HCl	IV	Antineoplastic - Alkylating Agent - Nitrogen Mustards
DEMEROL	meperidine HCl/PF	IJ	Analgesic Opioid Agonists
MESNEX	mesna	IV	Urinary Tract Protective Agents used in conjunction with Chemotherapy
REGLAN	metoclopramide HCl	IJ	Gastrointestinal Prokinetic Agents - D2 Antagonist/5-HT4 Agonists
MUTAMYCIN	mitomycin	IV	Antineoplastic Antibiotic - Others
JELMYTO	mitomycin	UR	Antineoplastic Antibiotic - Others
MITOXANTRONE HCL	mitoxantrone HCl	IV	Antineoplastic Antibiotic - Anthracyclines
LUMOXITI	moxetumomab pasudotox-tdfk	IV	Antineoplastic - Immunotoxins
ADSTILADRIN	nadofaragene firadenovec-vncg	IS	Antineoplastic - Gene Therapy Agents
DANYELZA	naxitamab-gqgk	IV	Antineoplastic - Anti-GD2 Ganglioside Monoclonal Antibody
PORTRAZZA	necitumumab	IV	Epidermal Growth Factor Recept Blocker (HER-1 Type), Rec-MC Antibody

Implementation: November 1, 2024

Brand Name	Generic Name	Route	Drug Class
ARRANON	nelarabine	IV	Antineoplastic - Antimetabolite - Purine Analogs
OPDIVO	nivolumab	IV	Antineoplastic-Anti-Programmed Cell Death Receptor-1 (PD-1) MC Antib.
SPINRAZA	nusinersen sodium/PF	IT	Spinal Muscular Atrophy - Exon Inclusion Antisense Oligonucleotide
GAZYVA	obinutuzumab	IV	Antineoplastic - CD20 Specific Recombinant Monoclonal Antibody Agents
JETREA	ocriplasmin	IVI	Ophthalmologicals
SANDOSTATIN	octreotide acetate	IJ	Somatostatic Agents
LARTRUVO	olaratumab	IV	Antineoplastic Monoclonal Antibodies
SYNRIBO	omacetaxine mepesuccinate	SQ	Antineoplastic -Cephalotaxines
NUZYRA	omadacycline tosylate	IV	Tetracycline Antibiotics
NEUMEGA	oprelvekin	SQ	Hematopoietic Growth Factor
ORBACTIV/ KIMYRSA	oritavancin diphosphate	IV	Lipoglycopeptide Antibiotics
OXACILLIN SODIUM	oxacillin sodium	IV	Penicillin Antibiotic - Penicillinase-resistant
OXALIPLATIN	oxaliplatin	IV	Antineoplastic - Platinum Complexes
PACLITAXEL PROTEIN-BOUND	paclitaxel protein-bound	IV	Antineoplastic - Taxanes
KEPIVANCE	palifermin	IV	Keratinocyte Growth Factor (KGF)
AREZIA	pamidronate disodium	IV	Bone Resorption Inhibitors - Bisphosphonates
VECTIBIX	panitumumab	IV	Epidermal Growth Factor Recept Blocker (HER-1 Type), Rec-MC Antibody
ZEMPLAR	paricalcitol	IV	Hyperparathyroid Treatment Agents - Vitamin D Analog-Type
SIGNIFOR	pasireotide diaspartate	SQ	Somatostatic Agents
SIGNIFOR LAR	pasireotide pamoate	IM	Somatostatic Agents

Implementation: November 1, 2024

Brand Name	Generic Name	Route	Drug Class
ONPATTRO	patisiran sodium, lipid complex	IV	Amyloidosis Agents-TTR Suppression, RNA Interfering (RNAi) based
ONCASPAR	pegaspargase	IJ	Antineoplastic - Asparaginase Enzyme Therapy Agents
PEMFEXY	pemetrexed	IV	Antineoplastic - Antimetabolite - Folic Acid Analogs
TALWIN	pentazocine	IM	Mixed Opiate Agonist-Antagonist
NIPENT	pentostatin	IV	Antineoplastic - Antimetabolite - Purine Analogs
RAPIVAB	peramivir/PF	IV	Influenza Antiviral Agents - Neuraminidase Inhibitors
PERJETA	pertuzumab	IV	Epidermal Growth Factor Recept (HER-2) Subdomain II Blocker, Rec-MC Ab
RYPLAZIM	plasminogen, human-tvmh	IV	Plasma Proteins Which Facilitate Anticoagulation
ZEMDRI	plazomicin sulfate	IV	Aminoglycoside Antibiotic
MOZOBIL	plerixafor	SQ	CXCR4 Chemokine Receptor Antagonists
POLIVY	polatuzumab vedotin-piiq	IV	Antineoplastic - Antibody-Drug Conjugates (ADCs)
FOLOTYN	pralatrexate	IV	Antineoplastic - Antimetabolite - Folic Acid Analogs
PROTAMINE SULFATE	protamine sulfate	IV	Reversal Agents - Heparin Antagonists
CYRAMZA	ramucirumab	IV	Antineoplastic - Vasc Endothelial Growth Factor Receptor (VEGFR) Antag
LUCENTIS	ranibizumab	IO	Ophthalmic - Macular Degeneration, Age-Related, Therapy Agents
ELITEK	rasburicase	IV	Hyperuricemia Therapy - Urate-Oxidase Enzyme-Type
LEXISCAN	regadenoson	IV	Diagnostic Drugs - Cardiovascular
VEKLURY	remdesivir	IV	SARS-CoV-2 Antiviral Agent - RNA Polymerase Inhibitors
RHOGAM ULTRA-FILTERED PLUS	Rho(D) immune globulin	IM	Immune Globulin - Rho(D)
TRUXIMA	rituximab-abbs	IV	Antineoplastic - CD20 Specific Recombinant Monoclonal Antibody Agents

Implementation: November 1, 2024

Brand Name	Generic Name	Route	Drug Class
RIABNI	rituximab-arrx	IV	Antineoplastic - CD20 Specific Recombinant Monoclonal Antibody Agents
RUXIENCE	rituximab-pvvr	IV	Antineoplastic - CD20 Specific Recombinant Monoclonal Antibody Agents
ISTODAX	romidepsin	IV	Antineoplastic - Histone deacetylase (HDAC) inhibitors
TRODELVY	sacituzumab govitecan-hziy	IV	Antineoplastic-TROP2 Directed Antibody-Topoisomerase I Inhib Conjugate
LEUKINE	sargramostim	IJ	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
PROVENGE	sipuleucel-T/lactated ringers solution	IV	Antineoplastic - Immunotherapy, Therapeutic Vaccines
FERRLECIT	sodium ferric gluconate complex in sucrose	IV	Minerals and Electrolytes - Iron
LANREOTIDE	somatuline	SQ	Systemic Hormonal Agents-Pituitary and Hypothalamic Hormones
ZANOSAR	streptozocin	IV	Antineoplastic Antibiotic - Others
SUFENTA	sufentanil citrate	IV	General Anesthetic Adjuncts - Opioid
MONJUVI	tafasitamab-cxix	IV	Antineoplastic - CD19 Specific Recombinant Monoclonal Antibody Agents
ELZONRIS	tagraxofusp-erzs	IV	Antineoplastic-CD123-Directed Cytotoxin (IL-3 and diphth.) Conjugate
ELELYSO	taliglucerase alfa	IV	Metabolic Disease Enzyme Replacement, Gaucher's Disease
IMLYGIC	talimogene laherparepvec	IJ	Antineoplastic - Immunotherapy, Virus-Based
VIBATIV	telavancin HCl	IV	Lipoglycopeptide Antibiotics
TORISEL	temsirolimus	IV	Antineoplastic - mTOR Kinase Inhibitors
TEPADINA	thiotepa	IJ	Antineoplastic - Alkylating Agent - Ethylenimines and Methylmelamines
TYGACIL	tigecycline	IV	Tetracycline Antibiotics
HYCAMTIN	topotecan HCl	IV	Antineoplastic - Topoisomerase I Inhibitors
TOPOTECAN HCL	topotecan HCl	IV	Antineoplastic - Topoisomerase I Inhibitors
YONDELIS	trabectedin	IV	Antineoplastic-Alkylating Agent-Tetrahydroisoquinoline and Derivatives

Implementation: November 1, 2024

Brand Name	Generic Name	Route	Drug Class
KANJINTI	trastuzumab-anns	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody
OGIVRI	trastuzumab-dkst	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody
ONTRUZANT	trastuzumab-dttb	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody
HERZUMA	trastuzumab-pkrb	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody
TRAZIMERA	trastuzumab-qyyp	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody
HERCESSI	trastuzumab-strf	IV	Epidermal Growth Factor Recept Blocker (HER-2 Type), Rec-MC Antibody
COSELA	trilaciclib dihydrochloride	IV	Bone Marrow Protective Agents used in conjunction with Chemotherapy
TRELSTAR	triptorelin pamoate	IM	Antineoplastic - LHRH (GnRH) Agonist Analog Pituitary Suppressants
VALSTAR	valrubicin	IS	Antineoplastic Antibiotic - Anthracyclines
VILTEPSO	viltolarsen	IV	Duchenne Muscular Dystrophy - Exon Skipping Antisense Oligonucleotide
VELBAN	vinblastine	IV	Antineoplastic - Vinca Alkaloids and Analogs
VINCASAR PFS	vincristine sulfate	IV	Antineoplastic - Vinca Alkaloids and Analogs
MARQIBO	vincristine sulfate liposomal	IV	Antineoplastic - Vinca Alkaloids and Analogs
NAVELBINE	vinorelbine tartrate	IV	Antineoplastic - Vinca Alkaloids and Analogs
LUXTURNA	voretigene neparvovec-rzyl	IO	Retinal Pigment Epithelial 65 kDa Protein (RPE65) Gene Therapy
VFEND IV	voriconazole	IV	Antifungal - Triazoles
RECLAST	zoledronic acid	IV	Bone Resorption Inhibitors - Bisphosphonates